GenScript ProBio is the subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine, biologics discovery and antibody protein drug to accelerate drug development for customers.
GenScript ProBio’s total cell and gene therapy solution covers CMC of plasmid and virus for IND filing as well as clinical manufacturing and commercial manufacturing. In terms of plasmid service, GenScript ProBio has established the largest commercial GMP plasmid manufacturing facility and is the company that supports the most clinical approvals for CGT drugs including mRNA vaccines, CAR-T in China. It also is the first GMP manufacturing platform to provide in vitro transcription (IVT) template linearized plasmids for mRNA vaccines and has supported several mRNA vaccine global enterprises to obtain clinical approvals. In terms of viral vector service, GenScript ProBio has a stable and high-yield viral vector platform. As the first lentiviral vector CDMO and the leading AAV supplier in China, it has established two core technology platforms: lentiviral vector and adeno-associated viral (AAV) vector. Both LVV suspension platform and AAV suspension platform own self-developed lentiviral vector suspension cell line. Our quality management systems ensure phase appropriate compliance, data integrity and traceability.
GenScript ProBio’s innovative solutions for biologics discovery and development include therapeutic antibody discovery (fully human transgenic mice, bispecific antibodies, single B cell screening technology), antibody engineering and antibody characterization. As of October 2021, GenScript ProBio have completed over 950 projects, including nearly 200 projects for antibody discovery of multi-transmembrane targets. In biologics development service, GenScript ProBio has built a DNA to GMP material platform, including stable cell line development, host cell license, process development, analytical development to clinical manufacturing, and offer fed-batch and perfusion process to meet the growing needs for antibody and protein drugs. GenScript ProBio has established 2600L GMP capacity which meets FDA, EMA and NMPA regulatory requirements, and has successfully delivered global IND approvals for more than ten projects.
Toward the mission of “Innovation through Collaboration”, GenScript ProBio is committed to helping customers shorten the timeline for the development of biological drugs from discovery to commercialization, significantly lowering R&D costs and building a healthier future.